Total Knee Replacement and Chemical Thromboprophylaxis: Current Evidence

E-ISSN： 1875-6212|9|1|33-41

ISSN： 1570-1611

Source： Current Vascular Pharmacology, Vol.9, Iss.1, 2011-01, pp. : 33-41

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Costs and outcomes of total hip and knee joint replacement for rheumatoid arthritis

By March L. Barcenilla A. Cross M. Lapsley H. Parker D. Brooks P.

Clinical Rheumatology, Vol. 27, Iss. 10, 2008-10 ,pp. : 1235-1242

Springer Publishing Company

Access to resources Recommend Favorite

Salmonella Septic Arthritis Complicating Rheumatoid Arthritis in a Patient with Total Knee Replacement

Medical Principles and Practice, Vol. 8, Iss. 3, 1999-09 ,pp. : 245-250

Karger

Access to resources Recommend Favorite

Prophylaxis of venous thromboembolism with subcutaneous melagatran in total hip or total knee replacement - results from Phase II studies

By Eriksson B.I. Ogren M. Eriksson U.G. Kalebo P. Ahnfelt L. Bjorkstrom S. Sjostedt . Folestad A. Arfwidsson A.-C. Elvander C.S. Frison L.

Thrombosis Research, Vol. 105, Iss. 5, 2002-03 ,pp. : 371-378

Elsevier

Access to resources Recommend Favorite

Current evidence base for chronic total occlusion revascularization

By Douglas Hannah Johnston Nicola G Bagnall Alan J Walsh Simon J

Interventional Cardiology, Vol. 5, Iss. 5, 2013-10 ,pp. : 541-548

Future Medicine

Access to resources Recommend Favorite

Low-Molecular-Weight Heparin: The Optimal Duration of Prophylaxis Against Postoperative Venous Thromboembolism After Total Hip or Knee Replacement

By Heit J.A.

Thrombosis Research, Vol. 101, Iss. 1, 2001-01 ,pp. : 163-173

Elsevier

Access to resources Recommend Favorite